{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:34:53Z","timestamp":1793162093415,"version":"4.5.0"},"reference-count":260,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010629","name":"Fulbright Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010629","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["1R01HL159304"],"award-info":[{"award-number":["1R01HL159304"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["2R01HL085844"],"award-info":[{"award-number":["2R01HL085844"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["1R01HL174001"],"award-info":[{"award-number":["1R01HL174001"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["1R01NS128180"],"award-info":[{"award-number":["1R01NS128180"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["U54 NS127758"],"award-info":[{"award-number":["U54 NS127758"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["1R61NS127285"],"award-info":[{"award-number":["1R61NS127285"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["1F31NS124337"],"award-info":[{"award-number":["1F31NS124337"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.pharmr.2025.100090","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T09:28:56Z","timestamp":1757755736000},"page":"100090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Recent advances in the pharmacology of voltage-gated ion channels"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8627-7208","authenticated-orcid":false,"given":"Diego","family":"Lopez-Mateos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3894-0180","authenticated-orcid":false,"given":"Brandon John","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3235-442X","authenticated-orcid":false,"given":"Adriana","family":"Hern\u00e1ndez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2325-4834","authenticated-orcid":false,"given":"Vladimir","family":"Yarov-Yarovoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4437-5763","authenticated-orcid":false,"given":"Heike","family":"Wulff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 2","key":"10.1016\/j.pharmr.2025.100090_bib1","first-page":"S145","article-title":"The concise guide to PHARMACOLOGY 2023\/24: ion channels","volume":"180","author":"Alexander","year":"2023","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100090_bib2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40122-024-00697-0","article-title":"Pharmacology and mechanism of action of suzetrigine, a potent and selective NaV1.8 pain signal inhibitor for the treatment of moderate to severe pain","volume":"14","author":"Osteen","year":"2025","journal-title":"Pain Ther"},{"issue":"121","key":"10.1016\/j.pharmr.2025.100090_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003120","article-title":"T-type calcium channel blockers that attenuate thalamic burst firing and suppress absence seizures","volume":"4","author":"Tringham","year":"2012","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100090_bib4","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1124\/mol.108.052704","article-title":"Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes","volume":"75","author":"Pennington","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100090_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/bph.70119","article-title":"The fast-dissociating D2 antagonist antipsychotic JNJ-37822681 is a neuronal Kv7 channel opener: Potential repurposing for epilepsy treatment","author":"Carotenuto","year":"2025","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib6","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1124\/pr.117.014456","article-title":"Ion channels in genetic epilepsy: from genes and mechanisms to disease-targeted therapies","volume":"70","author":"Oyrer","year":"2018","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmr.2025.100090_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1146\/annurev-pharmtox-010818-021757","article-title":"Structure and pharmacology of voltage-gated sodium and calcium channels","volume":"60","author":"Catterall","year":"2020","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100090_bib8","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1152\/physrev.00025.2020","article-title":"Sodium channelopathies of skeletal muscle and brain","volume":"101","author":"Mantegazza","year":"2021","journal-title":"Physiol Rev"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100090_bib9","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41580-024-00763-7","article-title":"Structural biology and molecular pharmacology of voltage-gated ion channels","volume":"25","author":"Huang","year":"2024","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100090_bib10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41573-019-0013-8","article-title":"Antibodies and venom peptides: new modalities for ion channels","volume":"18","author":"Wulff","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100090_bib11","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/nrd2983","article-title":"Voltage-gated potassium channels as therapeutic targets","volume":"8","author":"Wulff","year":"2009","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100090_bib12","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41587-025-02590-3","article-title":"Vertex's opioid-free drug for acute pain wins FDA approval","volume":"43","author":"Harrison","year":"2025","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100090_bib13","doi-asserted-by":"crossref","first-page":"691","DOI":"10.4155\/fmc.10.183","article-title":"Renaissance of ion channel research and drug discovery by patch clamp automation","volume":"2","author":"Fertig","year":"2010","journal-title":"Future Med Chem"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100090_bib14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1085\/jgp.200709946","article-title":"Ion channels as drug targets: the next GPCRs","volume":"131","author":"Kaczorowski","year":"2008","journal-title":"J Gen Physiol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2016.230","article-title":"A comprehensive map of molecular drug targets","volume":"16","author":"Santos","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"suppl 1","key":"10.1016\/j.pharmr.2025.100090_bib16","first-page":"S160","article-title":"THE CONCISE GUIDE TO PHARMACOLOGY 2017\/18: voltage-gated ion channels","volume":"174","author":"Alexander","year":"2017","journal-title":"Br J Pharmacol"},{"issue":"suppl 1","key":"10.1016\/j.pharmr.2025.100090_bib17","first-page":"S130","article-title":"THE CONCISE GUIDE TO PHARMACOLOGY 2017\/18: ligand-gated ion channels","volume":"174","author":"Alexander","year":"2017","journal-title":"Br J Pharmacol"},{"issue":"suppl 1","key":"10.1016\/j.pharmr.2025.100090_bib18","first-page":"S195","article-title":"THE CONCISE GUIDE TO PHARMACOLOGY 2017\/18: other ion channels","volume":"174","author":"Alexander","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100090_bib19","series-title":"Ion Channels of Excitable Membranes","author":"Hille","year":"2001"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100090_bib20","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s11064-017-2314-9","article-title":"Forty years of sodium channels: structure, function, pharmacology, and epilepsy","volume":"42","author":"Catterall","year":"2017","journal-title":"Neurochem Res"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100090_bib21","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1113\/JP272864","article-title":"Potassium channels in the heart: structure, function and regulation","volume":"595","author":"Grandi","year":"2017","journal-title":"J Physiol"},{"key":"10.1016\/j.pharmr.2025.100090_bib22","series-title":"Ion Channels as Targets in Drug Discovery","author":"Stephens","year":"2024"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib23","doi-asserted-by":"crossref","DOI":"10.1080\/19336950.2023.2281714","article-title":"Voltage gated sodium and calcium channels: discovery, structure, function, and Pharmacology","volume":"17","author":"Catterall","year":"2023","journal-title":"Channels"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100090_bib24","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-024-01108-x","article-title":"Voltage-gated sodium channels in excitable cells as drug targets","volume":"24","author":"Alsaloum","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"7121","key":"10.1016\/j.pharmr.2025.100090_bib25","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/nature05413","article-title":"An SCN9A channelopathy causes congenital inability to experience pain","volume":"444","author":"Cox","year":"2006","journal-title":"Nature"},{"issue":"29","key":"10.1016\/j.pharmr.2025.100090_bib26","doi-asserted-by":"crossref","first-page":"E2724","DOI":"10.1073\/pnas.1220844110","article-title":"Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels","volume":"110","author":"McCormack","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6267","key":"10.1016\/j.pharmr.2025.100090_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/science.aac5464","article-title":"Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist","volume":"350","author":"Ahuja","year":"2015","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100090_bib28","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1152\/physrev.00052.2017","article-title":"The role of voltage-gated sodium channels in pain signaling","volume":"99","author":"Bennett","year":"2019","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharmr.2025.100090_bib29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/164_2018_97","article-title":"Selective ligands and drug discovery targeting the voltage-gated sodium channel Nav1.7","volume":"246","author":"Payandeh","year":"2018","journal-title":"Handb Exp Pharmacol"},{"issue":"19","key":"10.1016\/j.pharmr.2025.100090_bib30","doi-asserted-by":"crossref","first-page":"8695","DOI":"10.1021\/acs.jmedchem.8b01906","article-title":"Challenges and opportunities for therapeutics targeting the voltage-gated sodium channel isoform NaV1.7","volume":"62","author":"Mulcahy","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmr.2025.100090_bib31","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.90960.3","article-title":"Similar excitability through different sodium channels and implications for the analgesic efficacy of selective drugs","volume":"12","author":"Xie","year":"2024","journal-title":"eLife"},{"key":"10.1016\/j.pharmr.2025.100090_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2021.147743","article-title":"Targeted augmentation of nuclear gene output (TANGO) of Scn1a rescues parvalbumin interneuron excitability and reduces seizures in a mouse model of Dravet syndrome","volume":"1775","author":"Wengert","year":"2022","journal-title":"Brain Res"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100090_bib33","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1111\/epi.18075","article-title":"Progress report on new medications for seizures and epilepsy: a summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). II. Drugs in more advanced clinical development","volume":"65","author":"Bialer","year":"2024","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100090_bib34","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ajhg.2018.10.023","article-title":"Aberrant inclusion of a poison exon causes Dravet syndrome and related SCN1A-associated genetic epilepsies","volume":"103","author":"Carvill","year":"2018","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100090_bib35","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1007\/s13311-021-01095-6","article-title":"Dravet syndrome: novel approaches for the most common genetic epilepsy","volume":"18","author":"Isom","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100090_bib36","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40263-023-01025-4","article-title":"New GABA-targeting therapies for the treatment of seizures and epilepsy: II. Treatments in clinical development","volume":"37","author":"Perucca","year":"2023","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100090_bib37","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/epi.17149","article-title":"The novel persistent sodium current inhibitor PRAX-562 has potent anticonvulsant activity with improved protective index relative to standard of care sodium channel blockers","volume":"63","author":"Kahlig","year":"2022","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100090_bib38","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1038\/s41591-025-03656-0","article-title":"Antisense oligonucleotide treatment in a preterm infant with early-onset SCN2A developmental and epileptic encephalopathy","volume":"31","author":"Wagner","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmr.2025.100090_bib39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1146\/annurev-neuro-070918-050144","article-title":"Sodium channels in human pain disorders: genetics and pharmacogenomics","volume":"42","author":"Dib-Hajj","year":"2019","journal-title":"Annu Rev Neurosci"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100090_bib40","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1111\/bph.15327","article-title":"Fifteen years of NaV1.7 channels as an analgesic target: why has excellent in vitro pharmacology not translated into in vivo analgesic efficacy?","volume":"179","author":"Eagles","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100090_bib41","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/j.pain.0000000000001227","article-title":"Efficacy of the Nav1.7 blocker PF-05089771 in a randomised, placebo-controlled, double-blind clinical study in subjects with painful diabetic peripheral neuropathy","volume":"159","author":"McDonnell","year":"2018","journal-title":"Pain"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100090_bib42","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1016\/j.celrep.2018.08.063","article-title":"Selective NaV1.7 antagonists with long residence time show improved efficacy against inflammatory and neuropathic pain","volume":"24","author":"Bankar","year":"2018","journal-title":"Cell Rep"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100090_bib43","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1021\/acs.jmedchem.1c00049","article-title":"Discovery of acyl-sulfonamide Nav1.7 inhibitors GDC-0276 and GDC-0310","volume":"64","author":"Safina","year":"2021","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100090_bib44","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s40261-019-00807-3","article-title":"Safety, tolerability, and pharmacokinetics of GDC-0276, a novel NaV1.7 inhibitor, in a first-in-human, single- and multiple-dose study in healthy volunteers","volume":"39","author":"Rothenberg","year":"2019","journal-title":"Clin Drug Investig"},{"issue":"17","key":"10.1016\/j.pharmr.2025.100090_bib45","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1111\/bph.16398","article-title":"ST-2560, a selective inhibitor of the NaV1.7 sodium channel, affects nocifensive and cardiovascular reflexes in non-human primates","volume":"181","author":"Mulcahy","year":"2024","journal-title":"Br J Pharmacol"},{"issue":"17","key":"10.1016\/j.pharmr.2025.100090_bib46","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1016\/j.neuron.2023.05.024","article-title":"Nav1.7 is essential for nociceptor action potentials in the mouse in a manner independent of endogenous opioids","volume":"111","author":"Deng","year":"2023","journal-title":"Neuron"},{"issue":"584","key":"10.1016\/j.pharmr.2025.100090_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay9056","article-title":"Long-lasting analgesia via targeted in situ repression of NaV1.7 in mice","volume":"13","author":"Moreno","year":"2021","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/acscentsci.3c00016","article-title":"Peptide nucleic acids promise new therapeutics and gene editing tools","volume":"9","author":"Brazil","year":"2023","journal-title":"ACS Cent Sci"},{"issue":"32","key":"10.1016\/j.pharmr.2025.100090_bib49","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2217800120","article-title":"Identification and targeting of a unique NaV1.7 domain driving chronic pain","volume":"120","author":"Gomez","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100090_bib50","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2209870","article-title":"Selective inhibition of NaV1.8 with VX-548 for acute pain","volume":"389","author":"Jones","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib51","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5582\/ddt.2025.01010","article-title":"Suzetrigine: the first Nav1.8 inhibitor approved for the treatment of moderate to severe acute pain","volume":"19","author":"Hu","year":"2025","journal-title":"Drug Discov Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100090_bib52","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1124\/molpharm.123.000789","article-title":"Pharmacologic characterization of LTGO-33, a selective small molecule inhibitor of the voltage-gated sodium channel NaV1.8 with a unique mechanism of action","volume":"105","author":"Gilchrist","year":"2024","journal-title":"Mol Pharmacol"},{"issue":"1\u20132","key":"10.1016\/j.pharmr.2025.100090_bib53","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0304-3959(97)00012-2","article-title":"Tetrodotoxin inhibits neuropathic ectopic activity in neuromas, dorsal root ganglia and dorsal horn neurons","volume":"72","author":"Omana-Zapata","year":"1997","journal-title":"Pain"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100090_bib54","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3390\/toxins13070483","article-title":"Tetrodotoxin, a potential drug for neuropathic and cancer pain relief?","volume":"13","author":"Gonzalez-Cano","year":"2021","journal-title":"Toxins"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib55","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0006-8993(00)02451-3","article-title":"Low dose of tetrodotoxin reduces neuropathic pain behaviors in an animal model","volume":"871","author":"Lyu","year":"2000","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmr.2025.100090_bib56","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/7212713","article-title":"Tetrodotoxin for moderate to severe cancer-related pain: a multicentre, randomized, double-blind, placebo-controlled, parallel-design trial","volume":"2017","author":"Hagen","year":"2017","journal-title":"Pain Res Manag"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100090_bib57","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jpain.2020.11.002","article-title":"Analgesic effects of topical amitriptyline in patients with chemotherapy-induced peripheral neuropathy: mechanistic insights from studies in mice","volume":"22","author":"Genevois","year":"2021","journal-title":"J Pain"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100090_bib58","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyae005","article-title":"Evenamide: a potential pharmacotherapeutic alternative for treatment-resistant schizophrenia","volume":"27","author":"Singh","year":"2024","journal-title":"Int J Neuropsychopharmacol"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100090_bib59","article-title":"Intra-channel bi-epitopic crosslinking unleashes ultrapotent antibodies targeting NaV1.7 for pain alleviation","volume":"5","author":"Zhang","year":"2024","journal-title":"Cell Rep Med"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100090_bib60","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s13311-022-01230-x","article-title":"The arrival of anti-CGRP monoclonal antibodies in migraine","volume":"19","author":"Cohen","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pharmr.2025.100090_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/srep39662","article-title":"Insensitivity to pain induced by a potent selective closed-state Nav1.7 inhibitor","volume":"7","author":"Flinspach","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharmr.2025.100090_bib62","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.81727","article-title":"Computational design of peptides to target NaV1.7 channel with high potency and selectivity for the treatment of pain","volume":"11","author":"Nguyen","year":"2022","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib63","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib64","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100090_bib65","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jacc.2018.04.082","article-title":"Etripamil nasal spray for rapid conversion of supraventricular tachycardia to sinus rhythm","volume":"72","author":"Stambler","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"10396","key":"10.1016\/j.pharmr.2025.100090_bib66","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0140-6736(23)00776-6","article-title":"Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial","volume":"402","author":"Stambler","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100090_bib67","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.122.010915","article-title":"First randomized, multicenter, placebo-controlled study of self-administered intranasal etripamil for acute conversion of spontaneous paroxysmal supraventricular tachycardia (NODE-301)","volume":"15","author":"Stambler","year":"2022","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100090_bib68","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.3390\/jcm14113720","article-title":"Efficacy and safety of intranasal etripamil for paroxysmal supraventricular tachycardia: meta-analysis of randomized controlled trials","volume":"14","author":"Jha","year":"2025","journal-title":"J Clin Med"},{"issue":"19","key":"10.1016\/j.pharmr.2025.100090_bib69","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028227","article-title":"Etripamil nasal spray for conversion of repeated spontaneous episodes of paroxysmal supraventricular tachycardia during long-term follow-up: results from the NODE-302 study","volume":"12","author":"Ip","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"9119","key":"10.1016\/j.pharmr.2025.100090_bib70","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(05)78800-0","article-title":"What lessons can be learnt from withdrawal of mibefradil from the market?","volume":"351","author":"Po","year":"1998","journal-title":"Lancet"},{"issue":"7787","key":"10.1016\/j.pharmr.2025.100090_bib71","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41586-019-1801-3","article-title":"Cryo-EM structures of apo and antagonist-bound human Cav3.1","volume":"576","author":"Zhao","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib72","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/j.pain.0000000000000362","article-title":"T-type calcium channel blocker Z944 restores cortical synchrony and thalamocortical connectivity in a rat model of neuropathic pain","volume":"157","author":"LeBlanc","year":"2016","journal-title":"Pain"},{"issue":"17","key":"10.1016\/j.pharmr.2025.100090_bib73","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1111\/bph.15498","article-title":"The T-type calcium channel antagonist, Z944, reduces spinal excitability and pain hypersensitivity","volume":"178","author":"Harding","year":"2021","journal-title":"Br J Pharmacol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100090_bib74","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/mds.28969","article-title":"Translational pharmacology of PRAX-944, a novel T-type calcium channel blocker in development for the treatment of essential tremor","volume":"37","author":"Scott","year":"2022","journal-title":"Mov Disord"},{"issue":"47","key":"10.1016\/j.pharmr.2025.100090_bib75","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2305215120","article-title":"A peptidomimetic modulator of the CaV2.2 N-type calcium channel for chronic pain","volume":"120","author":"Gomez","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100090_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpain.2024.104664","article-title":"Uncoupling the CRMP2-CaV2.2 interaction reduces pain-like behavior in a preclinical joint-pain model","volume":"25","author":"Allen","year":"2024","journal-title":"J Pain"},{"key":"10.1016\/j.pharmr.2025.100090_bib77","doi-asserted-by":"crossref","DOI":"10.1177\/1744806916642444","article-title":"A cell-permeant peptide corresponding to the cUBP domain of USP5 reverses inflammatory and neuropathic pain","volume":"12","author":"Garcia-Caballero","year":"2016","journal-title":"Mol Pain"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100090_bib78","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1021\/acschemneuro.1c00765","article-title":"A synthetically accessible small-molecule inhibitor of USP5-Cav3.2 calcium channel interactions with analgesic properties","volume":"13","author":"Garcia-Caballero","year":"2022","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.pharmr.2025.100090_bib79","first-page":"3704","article-title":"Development of tetrahydroquinoline-based inhibitors for chronic pain","volume":"15","author":"Patel","year":"2024","journal-title":"ACS Chem Neurosci"},{"issue":"17","key":"10.1016\/j.pharmr.2025.100090_bib80","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1113\/jphysiol.2010.191973","article-title":"Going native: voltage-gated potassium channels controlling neuronal excitability","volume":"588","author":"Johnston","year":"2010","journal-title":"J Physiol"},{"issue":"7083","key":"10.1016\/j.pharmr.2025.100090_bib81","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature04710","article-title":"hERG potassium channels and cardiac arrhythmia","volume":"440","author":"Sanguinetti","year":"2006","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100090_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199348","article-title":"Construction of an integrated database for hERG blocking small molecules","volume":"13","author":"Sato","year":"2018","journal-title":"PLoS One"},{"issue":"5950","key":"10.1016\/j.pharmr.2025.100090_bib83","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/307465a0","article-title":"Voltage-gated K+ channels in human T lymphocytes: a role in mitogenesis?","volume":"307","author":"DeCoursey","year":"1984","journal-title":"Nature"},{"issue":"5950","key":"10.1016\/j.pharmr.2025.100090_bib84","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/307468a0","article-title":"K channels in T lymphocytes: a patch clamp study using monoclonal antibody adhesion","volume":"307","author":"Matteson","year":"1984","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib85","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1600-065X.2009.00816.x","article-title":"The functional network of ion channels in T lymphocytes","volume":"231","author":"Cahalan","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.pharmr.2025.100090_bib86","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-immunol-032414-112212","article-title":"Ion channels in innate and adaptive immunity","volume":"33","author":"Feske","year":"2015","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100090_bib87","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.tips.2004.03.010","article-title":"K+ channels as targets for specific immunomodulation","volume":"25","author":"Chandy","year":"2004","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100090_bib88","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/cimm.1999.1569","article-title":"Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels","volume":"197","author":"Koo","year":"1999","journal-title":"Cell Immunol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100090_bib89","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0960-894X(03)00014-3","article-title":"Benzamide derivatives as blockers of the Kv1.3 ion channel","volume":"13","author":"Miao","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100090_bib90","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1172\/JCI16921","article-title":"The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS","volume":"111","author":"Wulff","year":"2003","journal-title":"J Clin Invest"},{"issue":"46","key":"10.1016\/j.pharmr.2025.100090_bib91","doi-asserted-by":"crossref","first-page":"17414","DOI":"10.1073\/pnas.0605136103","article-title":"Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases","volume":"103","author":"Beeton","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100090_bib92","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.immuni.2008.07.015","article-title":"Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block","volume":"29","author":"Matheu","year":"2008","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100090_bib93","first-page":"438","article-title":"Targeting effector memory T-cells with Kv1.3 blockers","volume":"10","author":"Wulff","year":"2007","journal-title":"Curr Opin Drug Discov Devel"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100090_bib94","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1124\/mol.104.008193","article-title":"Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases","volume":"67","author":"Beeton","year":"2005","journal-title":"Mol Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100090_bib95","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/jpet.112.191890","article-title":"Durable pharmacological responses from the peptide drug ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease","volume":"342","author":"Tarcha","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100090_bib96","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.toxicon.2011.07.016","article-title":"Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases","volume":"59","author":"Chi","year":"2012","journal-title":"Toxicon"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100090_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180762","article-title":"Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: a randomized phase 1b trial","volume":"12","author":"Tarcha","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmr.2025.100090_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2017.06.235","article-title":"Kv1.3 expression on effector memory T cells in sporadic inclusion body myositis: potential for targeted immunotherapy with dalazatide","volume":"27","author":"Mozaffar","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.pharmr.2025.100090_bib99","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.clim.2017.03.014","article-title":"Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog","volume":"180","author":"Tanner","year":"2017","journal-title":"Clin Immunol"},{"issue":"32","key":"10.1016\/j.pharmr.2025.100090_bib100","doi-asserted-by":"crossref","first-page":"9306","DOI":"10.1002\/anie.201603052","article-title":"Autocrine-based selection of drugs that target ion channels from combinatorial venom peptide libraries","volume":"55","author":"Zhang","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"issue":"33","key":"10.1016\/j.pharmr.2025.100090_bib101","doi-asserted-by":"crossref","first-page":"22704","DOI":"10.1074\/jbc.M114.568642","article-title":"Targeting the ion channel Kv1.3 with scorpion venom peptides engineered for potency, selectivity, and half-life","volume":"289","author":"Edwards","year":"2014","journal-title":"J Biol Chem"},{"issue":"17","key":"10.1016\/j.pharmr.2025.100090_bib102","doi-asserted-by":"crossref","first-page":"6784","DOI":"10.1021\/acs.jmedchem.5b00495","article-title":"Pharmaceutical optimization of peptide toxins for ion channel targets: potent, selective, and long-lived antagonists of Kv1.3","volume":"58","author":"Murray","year":"2015","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib103","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170102","article-title":"T cell subset and stimulation strength-dependent modulation of T cell activation by Kv1.3 blockers","volume":"12","author":"Fung-Leung","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmr.2025.100090_bib104","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14644","article-title":"Potassium channels Kv1.3 and KCa3.1 cooperatively and compensatorily regulate antigen-specific memory T cell functions","volume":"8","author":"Chiang","year":"2017","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100090_bib105","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1080\/19420862.2018.1445451","article-title":"A multiplatform strategy for the discovery of conventional monoclonal antibodies that inhibit the voltage-gated potassium channel Kv1.3","volume":"10","author":"Bednenko","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.pharmr.2025.100090_bib106","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.coi.2018.02.003","article-title":"Modulating ion channel function with antibodies and nanobodies","volume":"52","author":"Stortelers","year":"2018","journal-title":"Curr Opin Immunol"},{"issue":"41","key":"10.1016\/j.pharmr.2025.100090_bib107","doi-asserted-by":"crossref","first-page":"11501","DOI":"10.1073\/pnas.1612803113","article-title":"Rational design of a Kv1.3 channel-blocking antibody as a selective immunosuppressant","volume":"113","author":"Wang","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3 suppl 1","key":"10.1016\/j.pharmr.2025.100090_bib108","article-title":"Knotbodies: a new generation of ion channel therapeutic biologics created by fusing knottin toxins into antibodies","volume":"114","author":"Bell","year":"2018","journal-title":"Biophys J"},{"issue":"26","key":"10.1016\/j.pharmr.2025.100090_bib109","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.2174\/092986710792065072","article-title":"Use of Kv1.3 blockers for inflammatory skin conditions","volume":"17","author":"Nguyen","year":"2010","journal-title":"Curr Med Chem"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100090_bib110","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1002\/med.21800","article-title":"Discovery of KV1.3 ion channel inhibitors: medicinal chemistry approaches and challenges","volume":"41","author":"Gubic","year":"2021","journal-title":"Med Res Rev"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100090_bib111","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1124\/mol.105.015669","article-title":"Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases","volume":"68","author":"Schmitz","year":"2005","journal-title":"Mol Pharmacol"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100090_bib112","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.1073\/pnas.0911691107","article-title":"Principles of conduction and hydrophobic gating in K+ channels","volume":"107","author":"Jensen","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6078","key":"10.1016\/j.pharmr.2025.100090_bib113","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1126\/science.1216533","article-title":"Mechanism of voltage gating in potassium channels","volume":"336","author":"Jensen","year":"2012","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100090_bib114","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/ecco-jcc\/jjab078","article-title":"Suppressing Kv1.3 ion channel activity with a novel small molecule inhibitor ameliorates inflammation in a humanised mouse model of ulcerative colitis","volume":"15","author":"Unterweger","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100090_bib115","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1152\/physrev.00002.2017","article-title":"Kv3 channels: enablers of rapid firing, neurotransmitter release, and neuronal endurance","volume":"97","author":"Kaczmarek","year":"2017","journal-title":"Physiol Rev"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib116","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/ng.3144","article-title":"A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy","volume":"47","author":"Muona","year":"2015","journal-title":"Nat Genet"},{"issue":"suppl 2","key":"10.1016\/j.pharmr.2025.100090_bib117","first-page":"135","article-title":"Myoclonus epilepsy and ataxia due to potassium channel mutation (MEAK) is caused by heterozygous KCNC1 mutations","volume":"18","author":"Nascimento","year":"2016","journal-title":"Epileptic Disord"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100090_bib118","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1113\/JP271343","article-title":"Kv3.3 potassium channels and spinocerebellar ataxia","volume":"594","author":"Zhang","year":"2016","journal-title":"J Physiol"},{"key":"10.1016\/j.pharmr.2025.100090_bib119","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2024.1449151","article-title":"Voltage-gated potassium channels as a potential therapeutic target for the treatment of neurological and psychiatric disorders","volume":"18","author":"Faulkner","year":"2024","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.pharmr.2025.100090_bib120","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.neuropharm.2017.02.024","article-title":"Kv3.1\/Kv3.2 channel positive modulators enable faster activating kinetics and increase firing frequency in fast-spiking GABAergic interneurons","volume":"118","author":"Boddum","year":"2017","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100090_bib121","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/jpet.115.225748","article-title":"A novel modulator of Kv3 potassium channels regulates the firing of parvalbumin-positive cortical interneurons","volume":"354","author":"Rosato-Siri","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib122","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1038\/s41467-024-46813-8","article-title":"The binding and mechanism of a positive allosteric modulator of Kv3 channels","volume":"15","author":"Liang","year":"2024","journal-title":"Nat Commun"},{"issue":"42","key":"10.1016\/j.pharmr.2025.100090_bib123","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2220029120","article-title":"Identification, structural, and biophysical characterization of a positive modulator of human Kv3.1 channels","volume":"120","author":"Chen","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100090_bib124","doi-asserted-by":"crossref","DOI":"10.1093\/pnasnexus\/pgac083","article-title":"Apo and ligand-bound high resolution Cryo-EM structures of the human Kv3.1 channel reveal a novel binding site for positive modulators","volume":"1","author":"Botte","year":"2022","journal-title":"PNAS Nexus"},{"key":"10.1016\/j.pharmr.2025.100090_bib125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.heares.2019.03.018","article-title":"A balanced randomised placebo controlled blinded phase IIa multi-centre study to investigate the efficacy and safety of AUT00063 versus placebo in subjective tinnitus: the QUIET-1 trial","volume":"377","author":"Hall","year":"2019","journal-title":"Hear Res"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100090_bib126","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1177\/02698811221122031","article-title":"The effect of AUT00206, a Kv3 potassium channel modulator, on dopamine synthesis capacity and the reliability of [18F]-FDOPA imaging in schizophrenia","volume":"36","author":"Angelescu","year":"2022","journal-title":"J Psychopharmacol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100090_bib127","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/13543784.2023.2219385","article-title":"Potassium channel modulators and schizophrenia: an overview of investigational drugs","volume":"32","author":"Musselman","year":"2023","journal-title":"Exp Opin Investig Drugs"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100090_bib128","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/npp.2017.155","article-title":"Antimanic efficacy of a novel Kv3 potassium channel modulator","volume":"43","author":"Parekh","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100090_bib129","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/nrn1785","article-title":"Pathways modulating neural KCNQ\/M (Kv7) potassium channels","volume":"6","author":"Delmas","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.pharmr.2025.100090_bib130","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1152\/physiol.00031.2005","article-title":"The KCNQ1 potassium channel: from gene to physiological function","volume":"20","author":"Jespersen","year":"2005","journal-title":"Physiology"},{"issue":"6604","key":"10.1016\/j.pharmr.2025.100090_bib131","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/384080a0","article-title":"Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel","volume":"384","author":"Sanguinetti","year":"1996","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100090_bib132","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1161\/01.CIR.100.18.1917","article-title":"Antiarrhythmic efficacy of selective blockade of the cardiac slowly activating delayed rectifier current, I(Ks), in canine models of malignant ischemic ventricular arrhythmia","volume":"100","author":"Lynch","year":"1999","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100090_bib133","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/sj.bjp.0706721","article-title":"Blockade of IKs by HMR 1556 increases the reverse rate-dependence of refractoriness prolongation by dofetilide in isolated rabbit ventricles","volume":"148","author":"So","year":"2006","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100090_bib134","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s00395-005-0522-y","article-title":"The new selective I(Ks)-blocking agent HMR 1556 restores sinus rhythm and prevents heart failure in pigs with persistent atrial fibrillation","volume":"100","author":"Bauer","year":"2005","journal-title":"Basic Res Cardiol"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100090_bib135","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/j.1476-5381.2009.00111.x","article-title":"Neural KCNQ (Kv7) channels","volume":"156","author":"Brown","year":"2009","journal-title":"Br J Pharmacol"},{"issue":"5349","key":"10.1016\/j.pharmr.2025.100090_bib136","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.279.5349.403","article-title":"A potassium channel mutation in neonatal human epilepsy","volume":"279","author":"Biervert","year":"1998","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib137","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/ng0198-25","article-title":"A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns","volume":"18","author":"Singh","year":"1998","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100090_bib138","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/01.wnl.0000317090.92185.ec","article-title":"KCNQ2 and KCNQ3 mutations contribute to different idiopathic epilepsy syndromes","volume":"71","author":"Neubauer","year":"2008","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100090_bib139","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1111\/epi.16314","article-title":"Characteristics of KCNQ2 variants causing either benign neonatal epilepsy or developmental and epileptic encephalopathy","volume":"60","author":"Goto","year":"2019","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100090_bib140","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1039\/D0MD00328J","article-title":"Chemical modulation of Kv7 potassium channels","volume":"12","author":"Borgini","year":"2021","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.pharmr.2025.100090_bib141","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1146\/annurev-pharmtox-052120-104249","article-title":"KCNQ potassium channels as targets of botanical folk medicines","volume":"62","author":"Redford","year":"2022","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100090_bib142","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40263-024-01155-3","article-title":"Targeting Kv7 potassium channels for epilepsy","volume":"39","author":"Perucca","year":"2025","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100090_bib143","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/jamaneurol.2020.4300","article-title":"Effect of ezogabine on cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis: a randomized clinical trial","volume":"78","author":"Wainger","year":"2021","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100090_bib144","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/jamaneurol.2023.3542","article-title":"Efficacy and safety of XEN1101, a novel potassium channel opener, in adults with focal epilepsy: a phase 2b randomized clinical trial","volume":"80","author":"French","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.pharmr.2025.100090_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.heares.2020.107884","article-title":"Molecular basis and restoration of function deficiencies of Kv7.4 variants associated with inherited hearing loss","volume":"388","author":"Xia","year":"2020","journal-title":"Hear Res"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100090_bib146","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1111\/j.1476-5381.2011.01697.x","article-title":"Restoration of ion channel function in deafness-causing KCNQ4 mutants by synthetic channel openers","volume":"165","author":"Leitner","year":"2012","journal-title":"Br J Pharmacol"},{"issue":"6935","key":"10.1016\/j.pharmr.2025.100090_bib147","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nature01580","article-title":"X-ray structure of a voltage-dependent K+ channel","volume":"423","author":"Jiang","year":"2003","journal-title":"Nature"},{"issue":"5736","key":"10.1016\/j.pharmr.2025.100090_bib148","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1126\/science.1116269","article-title":"Crystal structure of a mammalian voltage-dependent Shaker family K+ channel","volume":"309","author":"Long","year":"2005","journal-title":"Science"},{"issue":"5736","key":"10.1016\/j.pharmr.2025.100090_bib149","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1126\/science.1116270","article-title":"Voltage sensor of Kv1.2: structural basis of electromechanical coupling","volume":"309","author":"Long","year":"2005","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib150","doi-asserted-by":"crossref","DOI":"10.1080\/19336950.2023.2287832","article-title":"A structural atlas of druggable sites on Nav channels","volume":"18","author":"Li","year":"2024","journal-title":"Channels"},{"issue":"7356","key":"10.1016\/j.pharmr.2025.100090_bib151","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature10238","article-title":"The crystal structure of a voltage-gated sodium channel","volume":"475","author":"Payandeh","year":"2011","journal-title":"Nature"},{"issue":"6328","key":"10.1016\/j.pharmr.2025.100090_bib152","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal4326","article-title":"Structure of a eukaryotic voltage-gated sodium channel at near-atomic resolution","volume":"355","author":"Shen","year":"2017","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100090_bib153","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.cell.2017.06.039","article-title":"Structure of the Nav1.4-\u03b21 complex from electric eel","volume":"170","author":"Yan","year":"2017","journal-title":"Cell"},{"issue":"6412","key":"10.1016\/j.pharmr.2025.100090_bib154","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau2486","article-title":"Structure of the human voltage-gated sodium channel Nav 1.4 in complex with \u03b21","volume":"362","author":"Pan","year":"2018","journal-title":"Science"},{"issue":"22","key":"10.1016\/j.pharmr.2025.100090_bib155","doi-asserted-by":"crossref","first-page":"10910","DOI":"10.1073\/pnas.89.22.10910","article-title":"A cluster of hydrophobic amino acid residues required for fast Na+-channel inactivation","volume":"89","author":"West","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100090_bib156","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1085\/jgp.201310998","article-title":"Domain IV voltage-sensor movement is both sufficient and rate limiting for fast inactivation in sodium channels","volume":"142","author":"Capes","year":"2013","journal-title":"J Gen Physiol"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100090_bib157","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1113\/jphysiol.2011.224204","article-title":"Voltage-gated sodium channels at 60: structure, function and pathophysiology","volume":"590","author":"Catterall","year":"2012","journal-title":"J Physiol"},{"issue":"6433","key":"10.1016\/j.pharmr.2025.100090_bib158","doi-asserted-by":"crossref","DOI":"10.1126\/science.aav8573","article-title":"Structural basis of \u03b1-scorpion toxin action on Nav channels","volume":"363","author":"Clairfeuille","year":"2019","journal-title":"Science"},{"issue":"6433","key":"10.1016\/j.pharmr.2025.100090_bib159","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1126\/science.aaw2493","article-title":"Structures of human Nav1.7 channel in complex with auxiliary subunits and animal toxins","volume":"363","author":"Shen","year":"2019","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100090_bib160","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.cell.2018.12.018","article-title":"Structural basis of Nav1.7 inhibition by a gating-modifier spider toxin","volume":"176","author":"Xu","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib161","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.cell.2019.11.041","article-title":"Structure of the cardiac sodium channel","volume":"180","author":"Jiang","year":"2020","journal-title":"Cell"},{"issue":"30","key":"10.1016\/j.pharmr.2025.100090_bib162","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2208211119","article-title":"Structural basis for high-voltage activation and subtype-specific inhibition of human Nav1.8","volume":"119","author":"Huang","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100090_bib163","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2100069118","article-title":"Structure of human Nav1.5 reveals the fast inactivation-related segments as a mutational hotspot for the long QT syndrome","volume":"118","author":"Li","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib164","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1038\/s41467-024-48125-3","article-title":"Structural mechanism of voltage-gated sodium channel slow inactivation","volume":"15","author":"Chen","year":"2024","journal-title":"Nat Commun"},{"issue":"6267","key":"10.1016\/j.pharmr.2025.100090_bib165","doi-asserted-by":"crossref","DOI":"10.1126\/science.aad2395","article-title":"Structure of the voltage-gated calcium channel Cav1.1 complex","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100090_bib166","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.cell.2019.04.043","article-title":"Molecular basis for ligand modulation of a mammalian voltage-gated Ca2+ channel","volume":"177","author":"Zhao","year":"2019","journal-title":"Cell"},{"issue":"7870","key":"10.1016\/j.pharmr.2025.100090_bib167","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41586-021-03699-6","article-title":"Structure of human Cav2.2 channel blocked by the painkiller ziconotide","volume":"596","author":"Gao","year":"2021","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100090_bib168","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41422-022-00663-5","article-title":"Structural basis for pore blockade of human voltage-gated calcium channel Cav1.3 by motion sickness drug cinnarizine","volume":"32","author":"Yao","year":"2022","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib169","doi-asserted-by":"crossref","first-page":"7358","DOI":"10.1038\/s41467-022-35026-6","article-title":"Structures of the R-type human Cav2.3 channel reveal conformational crosstalk of the intracellular segments","volume":"13","author":"Yao","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib170","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/s41467-022-29728-0","article-title":"Structure, gating, and pharmacology of human CaV3.3 channel","volume":"13","author":"He","year":"2022","journal-title":"Nat Commun"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100090_bib171","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1016\/j.cell.2023.10.007","article-title":"Structural basis for human Cav1.2 inhibition by multiple drugs and the neurotoxin calciseptine","volume":"186","author":"Gao","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib172","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1038\/s41467-024-47116-8","article-title":"Structural bases of inhibitory mechanism of CaV1.2 channel inhibitors","volume":"15","author":"Wei","year":"2024","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100090_bib173","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41422-024-00959-8","article-title":"Structural basis for human Cav3.2 inhibition by selective antagonists","volume":"34","author":"Huang","year":"2024","journal-title":"Cell Res"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100090_bib174","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41422-024-00940-5","article-title":"Structural basis for different omega-agatoxin IVA sensitivities of the P\u2013type and Q-type Cav2.1 channels","volume":"34","author":"Li","year":"2024","journal-title":"Cell Res"},{"issue":"7969","key":"10.1016\/j.pharmr.2025.100090_bib175","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-023-06175-5","article-title":"EMC chaperone-CaV structure reveals an ion channel assembly intermediate","volume":"619","author":"Chen","year":"2023","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100090_bib176","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cell.2017.03.048","article-title":"Cryo-EM Structure of the open human ether-a-go-go-related K+ channel hERG","volume":"169","author":"Wang","year":"2017","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100090_bib177","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.cell.2019.12.003","article-title":"Structural basis of human KCNQ1 modulation and gating","volume":"180","author":"Sun","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib178","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41422-020-00410-8","article-title":"Molecular basis for ligand activation of the human KCNQ2 channel","volume":"31","author":"Li","year":"2021","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib179","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.molcel.2020.10.037","article-title":"Structural basis for the modulation of human KCNQ4 by small-molecule drugs","volume":"81","author":"Li","year":"2021","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib180","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1038\/s41467-022-29594-w","article-title":"Cryo-EM structure of the human Kv3.1 channel reveals gating control by the cytoplasmic T1 domain","volume":"13","author":"Chi","year":"2022","journal-title":"Nat Commun"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100090_bib181","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm8804","article-title":"Structural basis for C-type inactivation in a Shaker family voltage-gated K+ channel","volume":"8","author":"Reddi","year":"2022","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib182","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1038\/s41467-022-31285-5","article-title":"Structures of the T cell potassium channel Kv1.3 with immunoglobulin modulators","volume":"13","author":"Selvakumar","year":"2022","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100090_bib183","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2113536119","article-title":"Rearrangement of a unique Kv1.3 selectivity filter conformation upon binding of a drug","volume":"119","author":"Tyagi","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7982","key":"10.1016\/j.pharmr.2025.100090_bib184","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-023-06582-8","article-title":"Inactivation of the Kv2.1 channel through electromechanical coupling","volume":"622","author":"Fernandez-Marino","year":"2023","journal-title":"Nature"},{"issue":"46","key":"10.1016\/j.pharmr.2025.100090_bib185","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2214151119","article-title":"Voltage-sensor movements in the Eag Kv channel under an applied electric field","volume":"119","author":"Mandala","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100090_bib186","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2301985120","article-title":"The membrane electric field regulates the PIP2-binding site to gate the KCNQ1 channel","volume":"120","author":"Mandala","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100090_bib187","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.str.2020.12.007","article-title":"Cryo-EM structure of K+-bound hERG channel complexed with the blocker astemizole","volume":"29","author":"Asai","year":"2021","journal-title":"Structure"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib188","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1038\/s41467-023-38942-3","article-title":"Structural mapping of Nav1.7 antagonists","volume":"14","author":"Wu","year":"2023","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100090_bib189","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1002\/anie.202011793","article-title":"Structural basis of the modulation of the voltage-gated calcium ion channel Cav1.1 by dihydropyridine compounds","volume":"60","author":"Gao","year":"2021","journal-title":"Angew Chem Int Ed"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100090_bib190","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41594-023-00951-7","article-title":"Structural basis for CaV\u03b12\u03b4:gabapentin binding","volume":"30","author":"Chen","year":"2023","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.pharmr.2025.100090_bib191","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00594","article-title":"Structure of a pore-blocking toxin in complex with a eukaryotic voltage-dependent K+ channel","volume":"2","author":"Banerjee","year":"2013","journal-title":"Elife"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100090_bib260","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2113536119","article-title":"Rearrangement of a unique Kv1.3 selectivity filter conformation upon binding of a drug","volume":"119","author":"Tyagi","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100090_bib192","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.neuron.2021.10.029","article-title":"Structural insights into the lipid and ligand regulation of a human neuronal KCNQ channel","volume":"110","author":"Zheng","year":"2022","journal-title":"Neuron"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100090_bib193","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nchembio.114","article-title":"Cortisone dissociates the Shaker family K+ channels from their beta subunits","volume":"4","author":"Pan","year":"2008","journal-title":"Nat Chem Biol"},{"issue":"5665","key":"10.1016\/j.pharmr.2025.100090_bib194","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1126\/science.1095920","article-title":"Protein kinase inhibitors: insights into drug design from structure","volume":"303","author":"Noble","year":"2004","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100090_bib195","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"7905","key":"10.1016\/j.pharmr.2025.100090_bib196","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/d41586-022-00997-5","article-title":"What's next for AlphaFold and the AI protein-folding revolution","volume":"604","author":"Callaway","year":"2022","journal-title":"Nature"},{"issue":"7969","key":"10.1016\/j.pharmr.2025.100090_bib197","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/d41586-023-02227-y","article-title":"AI tools are designing entirely new proteins that could transform medicine","volume":"619","author":"Callaway","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib198","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","article-title":"Artificial intelligence in drug development","volume":"31","author":"Zhang","year":"2025","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100090_bib199","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1021\/acs.jmedchem.7b01826","article-title":"Design of conformationally constrained acyl sulfonamide isosteres: identification of N-([1,2,4]triazolo[4,3- a]pyridin-3-yl)methane-sulfonamides as potent and selective hNaV1.7 inhibitors for the treatment of pain","volume":"61","author":"Focken","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmr.2025.100090_bib200","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.84151","article-title":"Cryo-EM reveals an unprecedented binding site for NaV1.7 inhibitors enabling rational design of potent hybrid inhibitors","volume":"12","author":"Kschonsak","year":"2023","journal-title":"Elife"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100090_bib201","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1021\/acs.jmedchem.8b01048","article-title":"Virtual chemical libraries","volume":"62","author":"Walters","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmr.2025.100090_bib202","article-title":"Targeting ion channels with ultra-large library screening for hit discovery","volume":"16","author":"Melancon","year":"2023","journal-title":"Front Mol Neurosci"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100090_bib203","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.1021\/acs.jcim.0c00675","article-title":"ZINC20\u2014a free ultralarge-scale chemical database for ligand discovery","volume":"60","author":"Irwin","year":"2020","journal-title":"J Chem Inf Model"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100090_bib204","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101681","article-title":"Generating multibillion chemical space of readily accessible screening compounds","volume":"23","author":"Grygorenko","year":"2020","journal-title":"iScience"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100090_bib205","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2174\/138620711795767802","article-title":"The design and application of target-focused compound libraries","volume":"14","author":"Harris","year":"2011","journal-title":"Comb Chem High Throughput Screen"},{"issue":"23","key":"10.1016\/j.pharmr.2025.100090_bib206","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.2174\/09298673113209990001","article-title":"Virtual screening strategies in drug discovery: a critical review","volume":"20","author":"Lavecchia","year":"2013","journal-title":"Curr Med Chem"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100090_bib207","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/prot.10465","article-title":"Improved protein-ligand docking using GOLD","volume":"52","author":"Verdonk","year":"2003","journal-title":"Proteins"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100090_bib208","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib209","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1021\/acs.jcim.9b00778","article-title":"Autodock vina adopts more accurate binding poses but Autodock4 forms better binding affinity","volume":"60","author":"Nguyen","year":"2020","journal-title":"J Chem Inf Model"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100090_bib210","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.bpj.2020.03.006","article-title":"Protein structure prediction and design in a biologically realistic implicit membrane","volume":"118","author":"Alford","year":"2020","journal-title":"Biophys J"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib211","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1011296","article-title":"Implicit model to capture electrostatic features of membrane environment","volume":"20","author":"Samanta","year":"2024","journal-title":"PLoS Comput Biol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100090_bib212","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1021\/ja026939x","article-title":"HADDOCK: a protein-protein docking approach based on biochemical or biophysical information","volume":"125","author":"Dominguez","year":"2003","journal-title":"J Am Chem Soc"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib213","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/bioinformatics\/btx555","article-title":"LightDock: a new multi-scale approach to protein-protein docking","volume":"34","author":"Jimenez-Garcia","year":"2018","journal-title":"Bioinformatics"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100090_bib214","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1021\/acs.jcim.0c00165","article-title":"Assessment of binding affinity via alchemical free-energy calculations","volume":"60","author":"Kuhn","year":"2020","journal-title":"J Chem Inf Model"},{"issue":"20","key":"10.1016\/j.pharmr.2025.100090_bib215","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2024215118","article-title":"Modulating the voltage sensor of a cardiac potassium channel shows antiarrhythmic effects","volume":"118","author":"Lin","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmr.2025.100090_bib216","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.49572","article-title":"Structure-based characterization of novel TRPV5 inhibitors","volume":"8","author":"Hughes","year":"2019","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib217","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12902-023-01360-z","article-title":"Targeting the inward rectifier potassium channel 5.1 in thyroid cancer: artificial intelligence-facilitated molecular docking for drug discovery","volume":"23","author":"Yang","year":"2023","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib218","doi-asserted-by":"crossref","first-page":"6784","DOI":"10.1038\/s41467-022-34359-6","article-title":"An allosteric modulator activates BK channels by perturbing coupling between Ca2+ binding and pore opening","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100090_bib219","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.3390\/molecules25122872","article-title":"Structure-based discovery of dual-target hits for acetylcholinesterase and the \u03b17 nicotinic acetylcholine receptors: in silico studies and in vitro confirmation","volume":"25","author":"Oddsson","year":"2020","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100090_bib220","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1021\/acscentsci.0c00229","article-title":"Deep docking: a deep learning platform for augmentation of structure based drug discovery","volume":"6","author":"Gentile","year":"2020","journal-title":"ACS Cent Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib221","doi-asserted-by":"crossref","first-page":"7761","DOI":"10.1038\/s41467-024-52061-7","article-title":"An artificial intelligence accelerated virtual screening platform for drug discovery","volume":"15","author":"Zhou","year":"2024","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100090_bib222","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1021\/acs.jcim.1c01250","article-title":"AtomNet PoseRanker: enriching ligand pose quality for dynamic proteins in virtual high-throughput screens","volume":"62","author":"Stafford","year":"2022","journal-title":"J Chem Inf Model"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib223","doi-asserted-by":"crossref","first-page":"7526","DOI":"10.1038\/s41598-024-54655-z","article-title":"AI is a viable alternative to high throughput screening: a 318-target study","volume":"14","year":"2024","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100090_bib224","article-title":"Deep generative molecular design reshapes drug discovery","volume":"3","author":"Zeng","year":"2022","journal-title":"Cell Rep Med"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100090_bib225","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1021\/acs.analchem.9b02348","article-title":"Deep learning to generate in silico chemical property libraries and candidate molecules for small molecule identification in complex samples","volume":"92","author":"Colby","year":"2020","journal-title":"Anal Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100090_bib226","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1039\/D0CP03620J","article-title":"Application and assessment of deep learning for the generation of potential NMDA receptor antagonists","volume":"23","author":"Schultz","year":"2021","journal-title":"Phys Chem Chem Phys"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib227","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13321-023-00694-z","article-title":"DrugEx v3: scaffold-constrained drug design with graph transformer-based reinforcement learning","volume":"15","author":"Liu","year":"2023","journal-title":"J Cheminform"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib228","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jmb.2014.07.027","article-title":"From foe to friend: using animal toxins to investigate ion channel function","volume":"427","author":"Kalia","year":"2015","journal-title":"J Mol Biol"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100090_bib229","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/S0041-0101(98)00149-4","article-title":"The cystine knot structure of ion channel toxins and related polypeptides","volume":"36","author":"Norton","year":"1998","journal-title":"Toxicon"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100090_bib230","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1016\/j.bmc.2017.09.029","article-title":"Peptide therapeutics from venom: current status and potential","volume":"26","author":"Pennington","year":"2018","journal-title":"Bioorg Med Chem"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100090_bib231","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1517\/14712598.2011.621940","article-title":"Venoms as a platform for human drugs: translating toxins into therapeutics","volume":"11","author":"King","year":"2011","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100090_bib232","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/14789450.2017.1377613","article-title":"Venom peptides as therapeutics: advances, challenges and the future of venom-peptide discovery","volume":"14","author":"Robinson","year":"2017","journal-title":"Expert Rev Proteomics"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100090_bib233","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1124\/mol.108.047670","article-title":"ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors","volume":"74","author":"Schmalhofer","year":"2008","journal-title":"Mol Pharmacol"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100090_bib234","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1021\/jm500687u","article-title":"Studies examining the relationship between the chemical structure of protoxin II and its activity on voltage gated sodium channels","volume":"57","author":"Park","year":"2014","journal-title":"J Med Chem"},{"issue":"34","key":"10.1016\/j.pharmr.2025.100090_bib235","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1021\/acs.biochem.6b00444","article-title":"Protocols for molecular modeling with Rosetta3 and RosettaScripts","volume":"55","author":"Bender","year":"2016","journal-title":"Biochemistry"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100090_bib236","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.4155\/fmc.14.98","article-title":"Computational approaches for designing potent and selective analogs of peptide toxins as novel therapeutics","volume":"6","author":"Kuyucak","year":"2014","journal-title":"Future Med Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100090_bib237","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1021\/jp410950h","article-title":"Free energy simulations of binding of HsTx1 toxin to Kv1 potassium channels: the basis of Kv1.3\/Kv1.1 selectivity","volume":"118","author":"Rashid","year":"2014","journal-title":"J Phys Chem B"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100090_bib238","doi-asserted-by":"crossref","DOI":"10.1085\/jgp.202313368","article-title":"Elucidating molecular mechanisms of protoxin-II state-specific binding to the human NaV1.7 channel","volume":"156","author":"Ngo","year":"2024","journal-title":"J Gen Physiol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib239","doi-asserted-by":"crossref","DOI":"10.1080\/19336950.2024.2325032","article-title":"Structural modeling of ion channels using AlphaFold2, RoseTTAFold2, and ESMFold","volume":"18","author":"Nguyen","year":"2024","journal-title":"Channels"},{"issue":"7873","key":"10.1016\/j.pharmr.2025.100090_bib240","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"issue":"6557","key":"10.1016\/j.pharmr.2025.100090_bib241","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1126\/science.abj8754","article-title":"Accurate prediction of protein structures and interactions using a three-track neural network","volume":"373","author":"Baek","year":"2021","journal-title":"Science"},{"issue":"7976","key":"10.1016\/j.pharmr.2025.100090_bib242","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41586-023-06415-8","article-title":"De novo design of protein structure and function with RFdiffusion","volume":"620","author":"Watson","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2025.100090_bib243","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-025-09429-6","article-title":"One-shot design of functional protein binders with BindCraft","author":"Pacesa","year":"2025","journal-title":"Nature"},{"issue":"7998","key":"10.1016\/j.pharmr.2025.100090_bib244","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41586-023-06953-1","article-title":"De novo design of high-affinity binders of bioactive helical peptides","volume":"626","author":"Vazquez Torres","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100090_bib245","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1152\/physiol.00029.2024","article-title":"Harnessing deep learning methods for voltage-gated ion channel drug discovery","volume":"40","author":"Lopez-Mateos","year":"2025","journal-title":"Physiology"},{"issue":"3 suppl 1","key":"10.1016\/j.pharmr.2025.100090_bib246","doi-asserted-by":"crossref","first-page":"295a","DOI":"10.1016\/j.bpj.2024.11.1654","article-title":"BPS2025-Diffusing protein binders to plug the sodium leak","volume":"124","author":"Usher","year":"2025","journal-title":"Biophys J"},{"issue":"3 suppl 1","key":"10.1016\/j.pharmr.2025.100090_bib247","article-title":"BPS2025\u2014A de novo designed miniprotein prevents Ca2+-feedback of CaV1 channels","volume":"124","author":"Yehya","year":"2025","journal-title":"Biophys J"},{"issue":"3 suppl 1","key":"10.1016\/j.pharmr.2025.100090_bib248","doi-asserted-by":"crossref","first-page":"539A","DOI":"10.1016\/j.bpj.2024.11.2816","article-title":"BPS2025\u2014Computational design of NaV1.8 sodium channel inhibitors as novel non-addictive treatments for pain management","volume":"124","author":"Narang","year":"2025","journal-title":"Biophys J"},{"issue":"25","key":"10.1016\/j.pharmr.2025.100090_bib249","first-page":"00860","article-title":"De novo design of a peptide modulator to reverse sodium channel dysfunction linked to cardiac arrhythmias and epilepsy","volume":"S0092-8674","author":"Mahling","year":"2025","journal-title":"Cell"},{"issue":"8016","key":"10.1016\/j.pharmr.2025.100090_bib250","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2025.100090_bib251","doi-asserted-by":"crossref","unstructured":"Wohlwend J, Corso G, Passaro S, et al. Boltz-1 democratizing biomolecular interaction modeling. Preprint. Posted online May 6, 2025. bioRxiv 624167. doi:10.1101\/2024.11.19.624167.","DOI":"10.1101\/2024.11.19.624167"},{"key":"10.1016\/j.pharmr.2025.100090_bib252","doi-asserted-by":"crossref","unstructured":"Bennett NR, Watson JL, Ragotte RJ, et al. Atomically accurate de novo design of antibodies with RFdiffusion. Preprint. Posted online February 28, 2025. bioRxiv 585103. doi:10.1101\/2024.03.14.585103.","DOI":"10.1101\/2024.03.14.585103"},{"key":"10.1016\/j.pharmr.2025.100090_bib253","doi-asserted-by":"crossref","DOI":"10.1038\/s41589-025-01929-w","article-title":"Accurate de novo design of high-affinity protein binding macrocycles using deep learning","author":"Rettie","year":"2025","journal-title":"Nat Chem Biol"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100090_bib254","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1021\/jacs.8b13178","article-title":"Macrocyclic peptides as drug candidates: recent progress and remaining challenges","volume":"141","author":"Vinogradov","year":"2019","journal-title":"J Am Chem Soc"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100090_bib255","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1161\/CIRCULATIONAHA.122.063372","article-title":"Orally bioavailable macrocyclic peptide that inhibits binding of PCSK9 to the low density lipoprotein receptor","volume":"148","author":"Johns","year":"2023","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100090_bib256","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1056\/NEJMoa2308713","article-title":"An oral interleukin-23-receptor antagonist peptide for plaque psoriasis","volume":"390","author":"Bissonnette","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100090_bib257","doi-asserted-by":"crossref","first-page":"210","DOI":"10.5582\/ddt.2025.01048","article-title":"Acoltremon: the first TRPM8 agonist approved for the treatment of dry eye disease","volume":"19","author":"Zhou","year":"2025","journal-title":"Drug Discov Ther"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100090_bib258","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1038\/s41591-025-03743-2","article-title":"A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial","volume":"31","author":"Xu","year":"2025","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100090_bib259","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1038\/s41591-025-03832-2","article-title":"AI-enabled drug discovery reaches clinical milestone","volume":"31","author":"Zitnik","year":"2025","journal-title":"Nat Med"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699725074988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699725074988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:45:47Z","timestamp":1773276347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699725074988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":260,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0031699725074988"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100090","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the pharmacology of voltage-gated ion channels","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100090"}}